09:33 AM EST - Medicenna Therapeutics Corp. : Announced its financial results and operational highlights for the fiscal year ended March 31, 2022. Net loss was $22.6 million, or $0.42 per share, compared to a loss of $17.3 million, or $0.35 per share for the year ended March 31, 2021. Medicenna Therapeutics Corp.
shares T.MDNA are trading unchanged at $1.11.
